Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Algernon Pharmaceuticals Inc (OP: AGNPF ) 0.0654 UNCHANGED Streaming Delayed Price Updated: 2:22 PM EDT, Oct 9, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 0.0654 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.0654 Today's Range 0.0654 - 0.0654 52wk Range 0.0353 - 0.1230 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More April 17, 2024 Via Benzinga DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design April 03, 2024 Via Benzinga Performance YTD +2.03% +2.03% 1 Month -19.56% -19.56% 3 Month -18.25% -18.25% 6 Month -8.53% -8.53% 1 Year -38.59% -38.59% More News Read More Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More August 14, 2023 Via Benzinga DMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 Study August 08, 2023 Via Benzinga Algernon Posts Mixed Bag Results From Mid Stage Chronic Cough Study July 18, 2022 Via Benzinga DMT's Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up June 05, 2023 Via Benzinga How To Finance A Psychedelics Business? Learn From These Four Companies April 04, 2023 Via Benzinga Intravenous DMT Therapy Seeks Ideal Dosage For Stroke And TBI Treatment April 04, 2023 Via Benzinga Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More March 07, 2023 Via Benzinga Algernon Pharmaceuticals AP-188 DMT Compound Shows Promise For The Treatment Of TBI March 03, 2023 Via Benzinga Algernon Pharmaceuticals Goes 4:1 In Forward Share Split After Announcing New TBI Program March 01, 2023 Via Benzinga Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More February 27, 2023 Via Benzinga Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More February 21, 2023 Via Benzinga Developing Psychedelic Treatments For Traumatic Brain Injury: Algernon Launches New Program February 21, 2023 Via Benzinga Algernon Touts Positive Study Findings, Confirms Next Trial Phase With Escalated Dose February 16, 2023 Via Benzinga A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing January 18, 2023 Via Benzinga Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One January 03, 2023 Via Benzinga EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans December 15, 2022 Via Benzinga Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More November 21, 2022 Via Benzinga Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon November 16, 2022 Via Benzinga Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video November 08, 2022 Via Newsfile Tackling Depression With Psychedelics: New Phase 2 Clinical Study Begins At Yale University October 24, 2022 Via Benzinga A Foundational Study On Stroke Is Ready. Here Is Why It's Important September 12, 2022 Via Benzinga Canadian Psychedelics Company To Begin First Global DMT Clinical Trial For Stroke Treatment September 08, 2022 Via Benzinga Algernon Pharmaceuticals Closes Private Placement Round, Announces New Shareholder Distribution August 23, 2022 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
